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Abstract
Introduction: With limited funds available, meeting global health targets requires countries to both mobilize and prioritize
their health spending. Within this context, countries have recognized the importance of allocating funds for HIV as efficiently
as possible to maximize impact. Over the past six years, the governments of 23 countries in Africa, Asia, Eastern Europe and
Latin America have used the Optima HIV tool to estimate the optimal allocation of HIV resources.
Methods: Each study commenced with a request by the national government for technical assistance in conducting an HIV
allocative efficiency study using Optima HIV. Each study team validated the required data, calibrated the Optima HIV epidemic
model to produce HIV epidemic projections, agreed on cost functions for interventions, and used the model to calculate the
optimal allocation of available funds to best address national strategic plan targets. From a review and analysis of these 23
country studies, we extract common themes around the optimal allocation of HIV funding in different epidemiological contexts.
Results and discussion: The optimal distribution of HIV resources depends on the amount of funding available and the char-
acteristics of each country’s epidemic, response and targets. Universally, the modelling results indicated that scaling up treat-
ment coverage is an efficient use of resources. There is scope for efficiency gains by targeting the HIV response towards the
populations and geographical regions where HIV incidence is highest. Across a range of countries, the model results indicate
that a more efficient allocation of HIV resources could reduce cumulative new HIV infections by an average of 18% over the
years to 2020 and 25% over the years to 2030, along with an approximately 25% reduction in deaths for both timelines.
However, in most countries this would still not be sufficient to meet the targets of the national strategic plan, with modelling
results indicating that budget increases of up to 185% would be required.
Conclusions: Greater epidemiological impact would be possible through better targeting of existing resources, but additional
resources would still be required to meet targets. Allocative efficiency models have proven valuable in improving the HIV plan-
ning and budgeting process.
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1 | INTRODUCTION
If decisions on the allocation of health resources were guided
by the principals of health economics alone, funds would be
allocated in ways intended to lead to the greatest reductions
in disease burden overall. However, economics is not – and
has never been – the sole factor influencing decisions on the
allocation of health funds. Such decisions are also influenced
by numerous other important factors, including the desires of
different funding bodies, the influence of other sectors, histor-
ical precedent, the desire to promote equity among vulnerable
or prioritized population groups, attempts to reduce financial
risk and the desire to maintain health security. In addition,
governments and other health funders are often challenged
by a lack of information about the cost-effectiveness and
impact of health interventions at a population level. The com-
bination of these factors means that the allocation of health
funds is often vastly different to how it would be under a
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purely population-level, evidence-based and health-outcome-
focused framework [1].
As with any component of health budgeting, planning an
HIV response can be an extremely time-consuming process.
To aid with this process, several different tools have been
developed and employed in different contexts, including the
widely used GOALS resource estimation tool, the Asian Epi-
demic model and the Optima HIV tool [2]. All three tools are
equipped with a resource requirements estimation feature
intended to help with budgeting. However, a unique feature of
the Optima HIV tool is its allocative efficiency optimization
algorithm. Within health economics, a response is described as
allocatively efficient if funds are allocated across different HIV
interventions and delivery modalities in the way that leads to
the best possible epidemic outcomes given any relevant con-
straints. This is particularly important in the current epidemio-
logical [3] and funding [4,5] context. Since 2002, an estimated
US$80.3 billion in development assistance for HIV pro-
grammes has been disbursed in over 100 lower-income coun-
tries [6]. However, the trend in funding over the past seven
years has been almost flat. Development assistance for HIV in
2015 totalled US$7.5 billion, which represented a 13%
decrease from 2014 levels (the first funding decrease in five
years) and brought the total amount of funding back to 2008
levels [6]. Thus, the question of how to get the most out of
the available HIV funding is more essential now than ever
before. It is now generally accepted that resource allocation
decisions should be informed by, or grounded in, explicit crite-
ria based on cost-effectiveness to maximize health benefits
with the resources available [7-20].
In this paper, we discuss and compare studies conducted
over six years and across 23 countries in Africa, Asia, East-
ern Europe and Latin America, each of which used Optima
HIV to estimate the potential gains that could be achieved
by reallocating resources in a more efficient way. We do not
intend to provide a formal meta-analysis, but rather a broad
qualitative comparison of the results that the modelling anal-
yses found in each context. By synthesizing the results, we
aim to identify common principles for the optimal allocation
of HIV resources.
2 | METHODS
The 23 studies included in this review were conducted in
Indonesia [21] and Vietnam [22] from the East Asia and Pacific
(EAP) region; Argentina [23], Colombia [24], Mexico [25], and
Peru [26] from the Latin America and Caribbean (LAC) region;
Armenia [27], Belarus [28], Bulgaria [29], Georgia [30], Kaza-
khstan [31], Kyrgyzstan [32], Macedonia [33], Moldova [34],
Tajikistan [35], Ukraine [36], and Uzbekistan [37] from the
Eastern Europe and Central Asia (EECA) region; Zambia [38]
from the Sub-Saharan Africa (SSA) region; and Cote d’Ivoire
[39], Niger [40], Senegal [41], Sudan [42], and Togo [43] from
the West and Central Africa (WCA) region. Studies were con-
ducted in partnership with institutions including the World
Bank, the Global Fund to fight AIDS, Tuberculosis and Malaria
(the Global Fund), the United States President’s Emergency
Plan for AIDS Relief (PEPFAR), the HIV Modelling Consortium,
the Joint United Nations Programme on HIV/AIDS (UNAIDS)
and the United Nations Development Programme (UNDP).
Although there was variation in the populations and pro-
grammes that were considered across the 23 studies, our
focus is on the similarities that emerge from applying the
same methodological framework for the analysis of the effi-
ciency of the HIV response. Thus, the criteria for inclusion in
this review were: (1) that the study was requested by the
government of the country in question; (2) that the Optima
HIV model was used to estimate the mathematically optimal
distribution of national HIV resources given government-speci-
fied epidemiological targets; (3) that the analysis represented
the entire country’s epidemic; (4) that the government agreed
for results to be released; and (5) that the study had not been
replaced by a more recent study that was already being
included. The first three criteria were applied in order to
ensure comparability of results, the fourth was added because
some of the studies were confidential and intended solely for
internal ministry purposes, and the fifth was added to avoid
redundancy. The 23 studies mentioned previously comprise
the full quota of studies that met these criteria. The Optima
HIV model was also used in other country studies, and in anal-
yses at sub-national regions, but these additional studies did
not meet the above criteria and thus were not included in this
review (see Table S1 for a complete listing).
The Optima HIV tool was designed and developed by the
Optima Consortium for Decision Science (the Optima Consor-
tium) with technical inputs and guidance from the World Bank.
The tool itself is based on a compartmental model of HIV
transmission and disease progression, and is capable of pro-
ducing estimates of epidemic trends, resource needs, and the
impact and cost-effectiveness of HIV responses. Furthermore,
it can estimate the allocation of resources across programmes
that best addresses national HIV targets while considering
various logistic, political and ethical constraints [44].
Each study commenced with a request, made to a devel-
opment agency by the national government, for technical
assistance in conducting an HIV allocative efficiency study.
In most cases, this request was made to the World Bank;
in two cases (Tajikistan and Uzbekistan) it was made to the
UNDP; and in six cases (Armenia, Belarus, Kazakhstan, Kyr-
gyzstan, Moldova and Ukraine), it was made to a group of
funding agencies. The agreement to conduct a study using
Optima HIV was then formalized on the basis of a scope of
work document that outlined the key policy questions for
the modelling analysis. An analytic team was then formed to
carry out the work agreed upon, with team members typi-
cally including representatives from the government (e.g.
from the ministry of health, the national team responsible
for monitoring and evaluation, or the national AIDS commis-
sion), from partnering organizations (e.g. the World Bank,
the Global Fund, UNDP, PEPFAR, UNAIDS) and from the
Optima Consortium. The analytic team then proceeded to
follow the steps outlined in Table 1. Reports with full
details of data, context, methods, results, interpretation and
discussion for all 23 countries are available either on the
Optima Consortium website (www.ocds.co) or the World
Bank’s Open Knowledge Repository, or can be made avail-
able upon request.
In this review, we analyze the findings across the 23 studies
using a thematic analysis, stipulating that these themes must
have been a conclusion of at least three studies before they
could be included in this review.
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Table 1. Steps in an allocative efficiency study, as followed for each of the countries considered in this review
Step Rationale Processes followed
Difficulties encountered and steps
taken to overcome them
1. Identify the
population groups
and HIV
programmes
suitable for
inclusion in the
analysis.
The burden of HIV varies
considerably within countries
according to factors such as
geography, behavioural tendencies,
age and sex. The population groups
included in an allocative efficiency
study should be selected to capture
this heterogeneity.
In all 23 studies, the entire national
population was stratified according
to age, sex and risk behaviour. In
addition, the population was further
stratified according to geographical
region in Moldova and Cote
d’Ivoire.
The desire to capture the particulars of
the epidemic dynamics must be
weighed up against the practical
constraints around data availability.
Criteria were defined to guide the
decision on whether to include a
population: the population should (a)
be clearly defined, (b) play a
substantial role in the country’s
epidemic, (c) currently or could be
targeted with HIV programmes, and (d)
have a minimum amount of data or
reliable estimates on population size
and HIV prevalence.
2. Collect and
validate the data
required for the
analysis.
A determination of how to optimally
target an HIV response must be
data-driven. Demographic,
behavioural and epidemiological
data for each population group
must be collected, as well as
programmatic data including unit
costs, expenditure and historical
levels of coverage (particularly
important for antiretroviral therapy
programmes) for each programme
and service delivery modality.
All available data were collected and
validated by the analytic teams.
In several contexts, there were data gaps
in the epidemiological, behavioural and
programmatic data. Often, this step
and the first step were conducted
iteratively, with populations being first
considered for inclusion and then later
removed if insufficient data were
available.
3. Calibrate the
model to available
data.
The calibration process involves
adjusting a subset of the model’s
parameters in order to minimize
the mean absolute percentage
error between the model’s
estimates and the observed data,
and then subjecting the projections
produced by the model to a
process of scrutiny and validation
by the district, province and
national health departments.
Typically, the model was calibrated to
historical data on HIV prevalence,
the number of HIV diagnoses, and
the number of people receiving
antiretroviral therapy, as well as
(where requested) the outputs of
other models that the country had
previously used.
Attaining a realistic calibration relies on
having good data to input to the
model. When difficulties were
experienced with calibrations, this
would often indicate issues with the
underlying data. In this sense, the
process of model calibration is
conducted synchronously with the
process of data validation.
4. Establish cost
functions.
Cost functions define a relationship
between spending on an HIV
service and the expected coverage
and outcome of that service
amongst the target population.
Each analytic team agreed on realistic
assumptions on both the maximal
attainable coverage for each
programme/modality and the
behavioural outcome expected to
prevail under that maximal
coverage level.
Data to inform cost functions is difficult
to obtain. In most cases, the cost
functions were partially informed by
data and partially be expert opinion.
5. Calculate the
optimal allocation
of available funds.
The allocation of funds that would
deliver the outcome closest to
national strategic targets can be
calculated using Optima’s
mathematical optimization
algorithm.
National strategic targets were
identified by the analytic teams,
usually in consultation with
ministries of health or other
responsible bodies.
In some cases, the initial optimization
produced a recommendation that the
country deemed politically or
programmatically infeasible. In such
cases, there was an option to rerun
the optimization with additional
constraints.
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Where possible, we supplement qualitative findings with
quantitative metrics. In particular: (a) we calculate the average
reduction in new infections and HIV-related deaths that was
estimated to be possible via a reallocation of funds; (b) we cal-
culate the average increase in treatment coverage that was
recommended based on the model findings; and (c) we calcu-
late correlation coefficients between the proportion of new
HIV infections acquired by each population (as defined by
age/risk/geographical location) and the share of the HIV pre-
vention budget that the model recommended should optimally
be targeted at these populations.
We note some limitations of the methods used in this
review to synthesize the results of the studies. Given the dif-
ferences in the inputs that were used for each study and the
outputs that were generated, it is challenging to make rigor-
ously quantitative comparative statements; thus, we have kept
our comparative analysis general and it should not be consid-
ered as a formal meta-analysis. The 23 studies included here
were conducted over a period of several years, and there
were various changes to the underlying model, the types of
data that were available, and the types of results that were
generated during this time. The predictions provided in these
studies are limited by the quality of the data and assumptions
used to inform them. In numerous settings, there were large
uncertainties and/or missing data for key input variables (such
as key population sizes, prevalence levels, and/or time trends).
Furthermore details of the particular limitations of each study
are included in the relevant reports.
3 | RESULTS AND DISCUSSION
3.1 | Estimated epidemiological impact
Across all 23 studies, the modelling results produced by the
Optima HIV tool indicated that by reallocating existing funds
for HIV, it would be possible to reduce both new HIV infec-
tions and HIV-related deaths. The magnitude of the epidemio-
logical reductions attainable would depend on multiple factors,
including the timeframe of consideration, epidemic type and
scale, the response profile and level of resourcing available. In
12 studies, the primary objective of analyses (aligned with
national strategic plans) was to minimize new infections by
2020; in these studies, the modelling results indicated that an
additional 18% (IQR 6% to 29%) reduction in new infections
would be attainable by optimally allocating resources (on top
of the reductions due to continuing current HIV responses). In
the eight studies where the time horizon for minimizing new
infections was 2030, an average reduction in new infections
of 25% (IQR 4% to 30%) was estimated to be possible
through better allocation of resources. (The remaining three
studies considered timelines to 2025 or 2010; see Table 2.)
Better targeting of resources was also able to further reduce
estimated deaths: by 22% (IQR 9% to 28%) on average
(across nine studies) by 2020, and by 29% (IQR 7% to 36%)
on average (across eight studies) by 2030. Details are summa-
rized in Table 2.
3.2 | Increased allocations to treatment
If no increases in the overall HIV budget are expected, the
analyses recommended increasing the share of HIV budgets
allocated to ART from 49% to 64% on average, which would
in turn increase estimated average national ART coverage
from 30% to 42% as a percentage of all PLHIV (Table 2).
The model’s recommendations to expand treatment had
important but varied consequences for the role of HIV testing
and counselling (HTC) programmes. In 14 countries, there
was known to be a large pool of people who had already been
diagnosed but were not on treatment. In these cases, the
modelling results indicated that it would be better to increase
funding to ART programmes first (including programmes link-
ing and retaining people to care), and that testing programmes
should not be scaled up until those already diagnosed had
been initiated on ART. This was consistently the case, even
when testing programmes were delivered via high-yield or
low-cost service modalities.
3.3 | Increased allocations to the populations with
the highest incidence
There was a marked correlation between the share of new
HIV infections acquired by each population and the share of
the HIV prevention budget that the model recommended
should be targeted to them. The correlation coefficient was
particularly high (0.77) for programmes targeted at PWID
(Figure 1a). The overall correlation coefficient was lower
(0.43) in the case of programmes for FSW, but this was
strongly influenced by the three countries from Western and
Table 1. (Continued)
Step Rationale Processes followed
Difficulties encountered and steps
taken to overcome them
6. Produce epidemic
trajectories.
The future evolution of the HIV
epidemic depends on the future of
the HIV response. The previous
analytic steps defined the nature of
this dependency, and determined
the response that would lead to
the best epidemic outcomes. The
final step translates these
responses into epidemic outcomes.
We projected the future evolution of
the epidemic assuming that the
future HIV budget was allocated (i)
as per the last reported HIV
spending pattern and (ii) as per the
optimal allocation of funds
calculated in the previous step.
The future of HIV funding is uncertain.
To account for this uncertainty,
epidemic projections were produced
under a range of different assumptions
about future budget availability.
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Central Africa in which rates of indirect sex work amongst the
general female population are high, so programmes targeted
to the general female population are likely to be effective
proxies. After removing these countries, we found a correla-
tion coefficient of 0.88 (Figure 1b). However, we found that
the correlation coefficient was lower for programmes targeted
at MSM (0.20; Figure 1c).
Almost all countries experience geographical variation in
both the severity of the HIV epidemic and in the costs of
delivering the HIV response. Often – especially in concen-
trated epidemics – there is significant overlap between the
geographical distribution of the HIV epidemic and the geo-
graphical distribution of the key affected populations, and as
a result it may be possible to ensure that the HIV response
is targeted at the right places simply by targeting the key
populations, where such populations can be safely found and
supported with programmes. However, in areas where there
is significant stigma and discrimination or where some key
population behaviour is illegal, geographic targeting as a
proxy for key population targeting might be needed in order
to ensure the safety of programme staff and the key popula-
tions themselves. When considering mixed and generalized
epidemics, the geographical distribution of the HIV epidemic
among the general population must also be taken into
account.
3.4 | Targeting the right delivery approaches to
maximize coverage
The question of how best to target the HIV response to the
appropriate populations and geographic areas is crucial, but it
must be considered alongside the equally important question
of how to deliver these HIV services at the highest possible
quality and the lowest feasible cost in ways that will reach a
wide variety of the intended populations. In general, informa-
tion on the heterogeneity of the costs and the impact of deliv-
ering HIV services both within and across countries is scarce,
and information on the determinants of this variation is even
scarcer. Across all 23 studies, significant attention was given
to the question of how the overall HIV response could be
improved by lowering costs while maintaining or improving
service delivery quality and modality to ensure the highest
coverage. In general, the recommendation was for countries
to rigorously review the costs of delivering their HIV
responses with a focus on both the unit costs of delivering
core HIV services and on the costs associated with
(a) (b)
(c)
Figure 1. The relationship between the share of infections in a particular population/district, and the share of the HIV budget for preven-
tion programmes. Results pertain to the year for which latest National AIDS Spending Accounts were available at the time study was con-
ducted – these years are presented in Table 2. The share of infections by sub-population was not available for Peru, Mexico, Colombia,
Argentina, Tajikistan or Ukraine. (a) PWID across 17 countries, (b) FSW across 17 countries, (c) MSM across 17 countries.
Stuart RM et al. Journal of the International AIDS Society 2018, 21:e25097
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25097/full | https://doi.org/10.1002/jia2.25097
9
management, human resources, administration, enablers, sup-
port and synergies.
With regard to unit costs of service delivery, we found large
heterogeneities both between countries and within countries.
Across the 11 studies completed in the Eastern Europe &
Central Asia region, there was significant variation in the unit
costs of ART, FSW programmes, MSM programmes, opiate
substitution therapy programmes, and needle-syringe pro-
grammes [45]. A separate study found large variation in the
unit costs of delivering needle-syringe programmes, opiate
substitution therapy, and ART across 52 sites in three oblasts
in Ukraine [46]. It can be difficult to distinguish intrinsic
heterogeneity from inefficiency, but benchmarking exercises
are the first step in identifying potential mechanisms for
streamlined service delivery.
It is also difficult to make a cross-country comparison of
expenditure on management and other supporting pro-
grammes, as methods for accounting for these costs vary sig-
nificantly across countries and not all costs were included in
all studies. It was not within the scope of these studies to
identify ways for strategic purchasing (or commissioning) for
reducing cost components of HIV responses, but many of the
stakeholders involved in the studies indicated that cost reduc-
tions were desired and potentially feasible.
3.5 | The optimal programme mix varies by
resource availability
In 16 of the 23 studies, the optimal distribution of the total
HIV budget under different funding constraints was estimated.
Across these studies, it was found that when very little money
is available, the optimal strategy is to focus on funding fewer
programmes in order to take advantage of economies of scale,
rather than continuing to fund the full mix of programmes at
lower levels. As more resources become available, the next
most cost-effective programmes should be introduced and
then scaled up. This was consistently the case across all 16
studies that contained this analysis (Table 2), and has been
explored in greater detail in a separate publication [47].
3.6 | More resources are required to achieve
national targets
In 13 of the 23 studies, the minimal level of investment
required to achieve the epidemiological targets described in
the country’s national strategic plan was estimated. In all but
one case (Macedonia), the amount being invested in the HIV
response at the time that the study was conducted was esti-
mated to be insufficient. The modelling results indicated that
budget increases up to 185% would be required to attain the
targets within the strategic plan timeframes (Table 2). This is
consistent with estimates published elsewhere of the
resources required to achieve global HIV targets [48]. Note
that these resource estimates pertain to the targets contained
in the national strategic plan that was in place at the time that
the study was conducted, which may since have changed. A
detailed description of the particular targets is contained in
each of the reports.
Knowledge of the funding environment and the likely
amount of resources that will be made available for HIV is an
essential component of planning an effective HIV response.
The majority of countries around the world have set ambitious
national targets for HIV reduction, yet have not invested or
acquired close to the level of resources for direct HIV pro-
grammes necessary to realistically achieve these targets, even
if their resources were invested in the best possible mix of
programmes. It may be possible to free up more funds for
core HIV services by improving the overall technical efficiency
of the HIV response – for example, via the integration of HIV
services into primary care, or by leveraging regional-level
negotiating power to bring down drug procurement costs –
but even after exploiting all possible gains from technical and
allocative efficiency improvements, it is almost certainly still
the case that additional funds will be required [48].
3.7 | Adoption of model recommendations
Allocative efficiency studies are most useful when conducted
prior to the budget- or target-setting process, so that they can
help inform health-related targets and determine the funding
envelopes and allocations commensurate with these targets.
The studies conducted in Sudan and Belarus represent two
examples from the suite of studies considered in this review
where the timing meant that the studies’ recommendations
(a)
(b)
Figure 2. Allocations of HIV budgets prior to Optima HIV study
(left bars), the mathematically optimal allocation recommended by
the Optima HIV analysis (middle bars) and the allocation that was
adopted by the country after the budgeting process was complete
(right bars). (a) Sudan (b) Belarus. Note that in Sudan, the total bud-
get envelope was decreased from US$12.3 m to US$9.9 m.
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could be taken into account in the budget-setting process, and
both countries ultimately shifted their HIV budget allocations
closer towards what the optimization analyses recommended
(Figure 2). Most other countries have used the results of the
Optima studies to inform their planning processes, resource
allocations or programmatic priorities. We hope to generate evi-
dence of these examples where modelling has been useful to
improve disease control strategies.
Analyses such as these are just one step in the process of
bringing about optimal resource allocation and maximum health
outcomes; the real challenge lies in mobilizing funding and
potentially changing the nature or type of programmes that pol-
icymakers implement. This can be challenging due to the multi-
tude of funding sources and the large proportion of HIV funding
that is dictated by external funding agendas and allocation crite-
ria. Policy recommendations will be most useful when they are
accompanied with an operational plan, supplemented with tech-
nical support, which sets out a clear pathway and implementa-
tion details. Whilst priority setting is a difficult process, it will
become increasingly important as countries move toward uni-
versal health coverage and will need to make decisions based
on objectives, health system users and cost-effectiveness.
4 | CONCLUSIONS
Our study collates the findings of 23 country analyses that
modelled how to optimally allocate the distribution of funds
across HIV programme areas in real-world budget allocation
decision-making. According to the results produced in these
country studies, it would be possible to achieve substantial
(5% to 30%) reductions in infections and deaths through bet-
ter targeting of existing resources. The findings also under-
score the benefits of additional resources targeted towards
HIV prevention and care. Having tools such as Optima HIV to
assist country decision-makers and their partners has value in
improving the HIV planning and budgeting process.
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